Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Application of berberine, coptisine or its active metabolites, and salts thereof in drugs for preventing and/or treating uric acid nephropathy

A technology of uric acid nephropathy and berberine, applied in the field of medicine, can solve problems such as adverse reactions, achieve the effects of improving renal function, improving uric acid metabolism, and preventing/treating uric acid nephropathy

Active Publication Date: 2022-05-20
INST OF MATERIA MEDICA CHINESE ACAD OF MEDICAL SCI
View PDF7 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, the main treatment methods are low-purine diet, drinking more water, maintaining urine volume, alkalizing urine, and using drugs that inhibit uric acid production and promote uric acid excretion, but most of the clinical medications have significant adverse reactions, which are worthy of our in-depth study

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of berberine, coptisine or its active metabolites, and salts thereof in drugs for preventing and/or treating uric acid nephropathy
  • Application of berberine, coptisine or its active metabolites, and salts thereof in drugs for preventing and/or treating uric acid nephropathy
  • Application of berberine, coptisine or its active metabolites, and salts thereof in drugs for preventing and/or treating uric acid nephropathy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0026] Embodiment 1. Therapeutic effect of berberine in yeast powder and adenine-induced uric acid nephropathy model SD rats.

[0027] Blood uric acid content, creatinine content, blood urea nitrogen content, left kidney weight index and rat kidney HE pathological comparison are important indicators to evaluate the therapeutic effect of uric acid nephropathy rats.

[0028] 1. Experimental animals, instruments and pharmaceutical reagents

[0029] SD rats (6 weeks old) were purchased from Beijing Weitong Lihua Animal Technology Co., Ltd., and the animals were kept in an SPF-grade environment (21±2°C, 12-hour light cycle), and they had free access to food and water during the experiment. Berberine was purchased from Bailingwei Company. Creatinine, uric acid, febuxostat, adenine, 4% tissue cell fixative and yeast powder were purchased from Beijing Suo Laibao Technology Company. The urea nitrogen test kit (urease method) was purchased from Nanjing Jiancheng Bioengineering Researc...

Embodiment 2

[0060] Example 2. The effect of palmatine on reducing uric acid in ICR mice.

[0061] The content of uric acid in blood is an important index to evaluate the therapeutic effect of uric acid nephropathy in rats.

[0062] 1. Experimental animals, instruments and pharmaceutical reagents

[0063] ICR mice (male, 20±2g) were purchased from Beijing Weitong Lihua Animal Technology Co., Ltd., and the animals were kept in an SPF environment (21±2°C, 12-hour light cycle), and they had free access to food and water during the experiment. Uric acid and yeast powder were purchased from Beijing Suolaibao Technology Co., Ltd., and palmatine was purchased from Chengdu Mansite Biotechnology Co., Ltd.

[0064] 2. Experimental design and animal grouping

[0065] Experimental Design: Experimental animals were divided into 3 groups, including control group, model group, and oral administration of palmatine 200mg / kg group. The modeling method was feeding with modeling feed, and the model was suc...

Embodiment 3

[0074] Example 3. The effect of jatrorrhizine on reducing uric acid in ICR mice.

[0075] The content of uric acid in blood is an important index to evaluate the therapeutic effect of uric acid nephropathy in rats.

[0076] 1. Experimental animals, instruments and pharmaceutical reagents

[0077] ICR mice (male, 20±2g) were purchased from Beijing Weitong Lihua Animal Technology Co., Ltd., and the animals were kept in an SPF environment (21±2°C, 12-hour light cycle), and they had free access to food and water during the experiment. Uric acid and yeast powder were purchased from Beijing Suolaibao Technology Co., Ltd., and jatrorrhizine was purchased from Chengdu Mansite Biotechnology Co., Ltd.

[0078] 2. Experimental design and animal grouping

[0079] Experimental Design: Experimental animals were divided into 3 groups, including control group, model group, and oral administration of jatrorrhizine 200 mg / kg. The modeling method was feeding with modeling feed, and the model ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses berberine represented by structural formula (I), coptisine represented by structural formula (II) or their active metabolites, and pharmaceutically acceptable salts thereof for the preparation of prevention and / or treatment of uric acid The application in nephropathy (gout nephropathy) medicine, and the active metabolite of berberine as shown in structural formula (III), (IV), (V), (VI), (VII), (VIII), (IX) comprises Jatrorrhizine, dihydroberberine, tangsongcaofen, berbererythrine, demethylene berberine, palmatine, and African tetrandrine.

Description

technical field [0001] The invention relates to the application of berberine, coptisine or active metabolites thereof, and pharmaceutically acceptable salts thereof in the preparation of medicaments for preventing and / or treating uric acid nephropathy; it belongs to the technical field of medicine. Background technique [0002] Uric acid nephropathy is kidney damage caused by excessive production of blood uric acid or decreased excretion of hyperuricemia, also known as gouty nephropathy, may have elevated uric acid, uric acid stones, proteinuria, edema, nocturia, hypertension , hematuria and renal tubular dysfunction. The disease has no obvious seasonality, and the incidence rate of obesity, carnivore and alcoholism is high, and the incidence rate of men is higher than that of women, and 85% of the patients are middle-aged and elderly people. In patients with uric acid nephropathy, the concentration of urate in the blood increases to a supersaturated state, and urate crysta...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/4375A61P19/06A61P13/12
CPCA61K31/4375A61P19/06A61P13/12Y02A50/30
Inventor 蒋建东王琰潘利斌赵朕雄丛林
Owner INST OF MATERIA MEDICA CHINESE ACAD OF MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com